GCTK Stock Overview A medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
GlucoTrack, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for GlucoTrack Historical stock prices Current Share Price US$0.42 52 Week High US$99.00 52 Week Low US$0.40 Beta -0.38 1 Month Change -75.27% 3 Month Change -91.60% 1 Year Change -98.16% 3 Year Change -99.88% 5 Year Change -99.93% Change since IPO -99.99%
Recent News & Updates GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.033748 million. Feb 05
Glucotrack, Inc. Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor Feb 04
GlucoTrack Announces Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Price Requirement Jan 31
GlucoTrack, Inc. Announces Chief Financial Officer Changes Jan 30
Glucotrack, Inc Appoints Peter C. Wulff as Chief Financial Officer Jan 29
GlucoTrack, Inc. Receives Nasdaq Non-Compliance Letter Regarding Bid Price Rule Jan 01 See more updates GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.033748 million. Feb 05
Glucotrack, Inc. Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor Feb 04
GlucoTrack Announces Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Price Requirement Jan 31
GlucoTrack, Inc. Announces Chief Financial Officer Changes Jan 30
Glucotrack, Inc Appoints Peter C. Wulff as Chief Financial Officer Jan 29
GlucoTrack, Inc. Receives Nasdaq Non-Compliance Letter Regarding Bid Price Rule Jan 01 GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $8.23 million. Dec 18
GlucoTrack, Inc. Announces Start of Enrollment for Human Clinical Study of Continuous Blood Glucose Monitor Dec 03 GlucoTrack, Inc. has completed a Follow-on Equity Offering in the amount of $9.995237 million. Nov 15
Glucotrack, Inc. Appoints John Ballantyne to Its Board of Directors Sep 03 GlucoTrack, Inc. announced that it has received $0.1 million in funding Jul 02
Glucotrack Announces the Appointment of Andy Balo to Board of Directors Jun 20
Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring Sensor Jun 15
Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose Monitor Jun 06
GlucoTrack Receives a Third Letter from Nasdaq Notifies Not Regains Compliance with the Minimum Bid Price Requirement During the Extended Compliance Period May 25
Glucotrack’s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study May 18
Glucotrack Announces Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Requirement May 17 GlucoTrack, Inc. announced that it has received $0.5 million in funding Apr 23
GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring Apr 18
Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor Apr 03
GlucoTrack, Inc., Annual General Meeting, Apr 26, 2024 Apr 02
Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors Feb 13
GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor Jan 03 GlucoTrack, Inc. Announces Executive Changes Oct 13
Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee Sep 01
Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor Jul 26
GlucoTrack Receives Letter from Nasdaq Regarding No Longer Complies with Nasdaq's Listing Rule 5550(a)(2) Jun 03
Nasdaq Issues a Letter to GlucoTrack Granting an Extension Until May 22, 2023 to Obtain Compliance Feb 14
Glucotrack to Begin Research & Development of Novel Continuous Glucose Monitoring System Oct 11
GlucoTrack to start R&D program for glucose monitoring system Oct 10
GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor Jun 23
Shalom Shushan, Chief Technology Officer, Provides Notice of His Resignation from Glucotrack, Inc., Effective May 22, 2022 Mar 29
Integrity Applications, Inc. announced delayed 10-Q filing May 18
Integrity Applications, Inc. announced delayed annual 10-K filing Apr 02
Integrity Applications, Inc. Announces Executive Changes Feb 10
Integrity Applications Appoints Paul V. Goode to Board of Directors Dec 19
Integrity Applications, Inc. Appoints Shalom Shushan as Chief Technology Officer, Effective November 9, 2020 Nov 06
Integrity Applications, Inc. Announces Resignation of Eugene Naidis as Vice President of R&D, Effective December 31, 2020 Oct 10 Shareholder Returns GCTK US Medical Equipment US Market 7D -20.8% -0.3% 1.2% 1Y -98.2% 11.6% 23.7%
See full shareholder returns
Return vs Market: GCTK underperformed the US Market which returned 23.7% over the past year.
Price Volatility Is GCTK's price volatile compared to industry and market? GCTK volatility GCTK Average Weekly Movement 32.0% Medical Equipment Industry Average Movement 8.0% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.0%
Stable Share Price: GCTK's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GCTK's weekly volatility has increased from 26% to 32% over the past year.
About the Company GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021.
Show more GlucoTrack, Inc. Fundamentals Summary How do GlucoTrack's earnings and revenue compare to its market cap? GCTK fundamental statistics Market cap US$4.71m Earnings (TTM ) -US$14.91m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GCTK income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$14.92m Earnings -US$14.91m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.44 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -54.5%
How did GCTK perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/19 23:35 End of Day Share Price 2025/02/19 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources GlucoTrack, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
